再発性小細胞肺癌（SCLC）患者を対象としたGSK5764227の研究
基本情報
- NCT ID
- NCT07099898
- ステータス
- 募集中
- 試験のフェーズ
- 第3相
- 試験タイプ
- 介入
- 目標被験者数
- 300
- 治験依頼者名
- GlaxoSmithKline
概要
"In this study researchers are testing GSK5764227, a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancers ability to grow and spread. This study specifically aims to evaluate how well GSK5764227 works in treating relapsed SCLC compared to standard treatment topotecan, by checking whether GSK5764227 makes cancers smaller or disappear completely and if it helps participants live longer. The study is also assessing whether GSK576227 is safe and tolerated well by participants compared to topotecan and provide a better understanding of the main side effects of both drugs. Participants with relapsed SCLC will be randomly divided into two groups: one group receiving GSK5764227 and the other receiving topotecan."
対象疾患
介入
依頼者（Sponsor）
実施施設 (15)
GSK Investigational Site
Osaka, Japan(RECRUITING)
独立行政法人国立病院機構京都医療センター
Kyoto, Japan(RECRUITING)
九州大学病院
Fukuoka, Japan(RECRUITING)
GSK Investigational Site
Mie, Japan(RECRUITING)
鹿児島大学病院
Kagoshima, Japan(RECRUITING)
地方独立行政法人東京都立病院機構 東京都立駒込病院
Tokyo, Japan(RECRUITING)
GSK Investigational Site
Osaka, Japan(RECRUITING)
GSK Investigational Site
Kanagawa, Japan(RECRUITING)
GSK Investigational Site
Kochi, Japan(RECRUITING)
GSK Investigational Site
Osaka, Japan(RECRUITING)
石川県立中央病院
Ishikawa, Japan(RECRUITING)
北里大学病院
Kanagawa, Japan(RECRUITING)
日本医科大学付属病院
Tokyo, Japan(RECRUITING)
北海道大学病院
Hokkaido, Japan(RECRUITING)
富山県立中央病院
Toyama, Japan(RECRUITING)